Jci_page_head_homepage_01 Jci_page_head_homepage_02
Thomas H. Langenickel, Michelle Olive, Manfred Boehm, Hong San, Martin F. Crook, Elizabeth G. Nabel
Published in Volume 118, Issue 12
J Clin Invest. 2008; 118(12):3848–3859 doi:10.1172/JCI33206
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 8
Stathmin degradation is determined by KIS-mediated phosphorylation of stathmin at serine 38.

(A) VSMCs were serum starved for 72 hours or released for 12 hours, with or without treatment with the proteasome inhibitor LC. Cell cycle–dependent degradation of stathmin in KIS+/+ VSMCs was inhibited by LC treatment and matched the stathmin level in serum-starved KIS+/+ VSMCs, as measured by Western blot in the cytoplasmic protein fraction. LC treatment had little or no effect on stathmin protein expression in KIS–/– VSMCs. GAPDH served as loading control. (B) Kinase assays using KIS or the kinase-deficient mutant K54R as kinases and recombinant stathmin (st) or phosphorylation site mutants of stathmin as substrates. KIS phosphorylated stathmin and stathminS25A (p-Stathmin). Phosphorylation of stathminS38A and stathminS25/38A was highly reduced or not detectable, which suggests that KIS phosphorylates stathmin at serine 38. Autophosphorylation of KIS (p-KIS) demonstrated equal KIS activity and effective reduction of kinase activity of K54R. Coomassie staining demonstrated equal loading. (C) Control experiment demonstrating that p34cdc2 phosphorylated stathmin, but not stathminS25/38A, whereas PKA phosphorylated both substrates. (D) Half-life of stathmin was measured after coexpression of stathmin or stathmin phosphorylation site mutants along with KIS or K54R in HEK293 cells, followed by cycloheximide treatment.